Generic ICD programming and outcomes
Introduction Generic ICD programming, where shock‐reduction programming is extrapolated from trials of one manufacturer to another, may reduce non‐essential ICD therapies beyond that seen in randomized trials. However, the benefits and risks are unknown. The purpose of this retrospective cohort stud...
Gespeichert in:
Veröffentlicht in: | Pacing and clinical electrophysiology 2021-12, Vol.44 (12), p.1995-2004 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Introduction
Generic ICD programming, where shock‐reduction programming is extrapolated from trials of one manufacturer to another, may reduce non‐essential ICD therapies beyond that seen in randomized trials. However, the benefits and risks are unknown. The purpose of this retrospective cohort study was to evaluate the impact of a standardized programming protocol, based on generic programming, across manufacturers.
Methods
We included all new ICDs in a single center (2009–2019). In 2013 a standardized programming protocol based on generic programming was introduced, incorporating high detection rates (200 bpm for primary prevention) and long detection (30/40 or equivalent in VF zone) for all patients. Patients were classified into three groups based on implant programming: pre‐guideline (PS), post‐guideline and guideline compliant (GC) and post‐guideline but not guideline compliant (NGC). The end‐points were the first occurrence of any device therapy (ATP or shock), ICD shock, syncope and all‐cause mortality. Survival analysis was used to evaluate outcomes.
Results
1003 patients were included (mean follow‐up 1519 ± 1005 days). In primary prevention patients (n = 583) freedom from ICD therapy (91.5% vs. 73.6%, p |
---|---|
ISSN: | 0147-8389 1540-8159 |
DOI: | 10.1111/pace.14386 |